CorWave
CorWave develops blood pumps based on a unique and patented wave membrane pumping technology. The membrane is the result of more than twenty years of research and development, and is capable of mimicking the native heart. This disruptive technology radically differentiates CorWave products from commercially-available rotary pump LVADs.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Active
Website
www.corwave.com
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Anne Osdoit
Partner, Sofinnova Partners MD Start Strategy
Related Articles
5 Sofinnova Partners portfolio companies selected to French Tech 120
CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor
CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program
CorWave’s next-generation LVAD, Neptune, receives funding
Corwave- Start-up & Co - BFM 04/01/2017
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.